PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Recently Added NEW Latest cases added to the library
AUTH/3282/11/19
Gilead Sciences Europe
Social Media & Digital · 2019
▶ Video 🎧 Podcast
AUTH/2991/11/17
Pfizer
Samples & Gifts · 2015
▶ Video 🎧 Podcast
AUTH/2082/1/08
Recordati Pharmaceuticals
Promotional Material · 2019
▶ Video 🎧 Podcast
AUTH/2079/1/08
Gamble Pharmaceuticals UK
Transfers of Value · 2008
▶ Video 🎧 Podcast
AUTH/2102/2/08
Meda Pharmaceuticals
Transfers of Value · 2008
▶ Video 🎧 Podcast
AUTH/2149/7/08
Syner-Med
Promotional Material · 2008
▶ Video 🎧 Podcast
AUTH/2428/8/11
AstraZeneca
Scientific Information · 2008
▶ Video 🎧 Podcast
AUTH/1899/10/06
AstraZeneca
Samples & Gifts · 2019
▶ Video 🎧 Podcast
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 218 results · Oncology  · Clear
🔒 Subscribers only
AUTH/3875/02/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
LinkedIn post mentioning Arexvy in financial results video (No breach)
An anonymous, non-contactable complainant alleged a GSK global leader improperly mentioned a product name in a LinkedIn post visible to the public, amounting to promotion of a prescription-only med…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3871/1/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AbbVie breach for inaccurate SPC presentation on EMC
An anonymous, non-contactable health professional complained about a formatting error in the Venclyxto (venetoclax) 100mg SPC on the EMC website.In section 4.2 (Posology and method of administratio…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3879/2/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Pfizer
An independent cancer research charitable organisation posted on LinkedIn about “a new drug, talazoparib” becoming an NHS targeted treatment for advanced breast cancers caused by BRCA mutations…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3905/5/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Nexplanon ad and linked website challenged for missing contraindications (no breach)
An anonymous, contactable healthcare professional complained about a Nexplanon advertisement shown on a closed community professional network for UK doctors.The complainant alleged the ad omitted �…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3891/4/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AbbVie breached Clause 8.5 after failing to recertify an AbbVie Pro landing page within two years (A
An anonymous, non-contactable complainant (member of the public/media) alleged that an AbbVie Pro oncology webpage showed a certification date of May 2020 and had not been recertified within two ye…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3920/6/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
A named complainant (describing themselves as a physician) complained about content in the ‘Experience’ section of a senior AstraZeneca employee’s LinkedIn profile.The complainant alleged the…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3901/5/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Complainant v GSK
A health professional complained about four webpages within GSK’s UK HCP promotional site (GSKPro) for Jemperli (dostarlimab). They alleged the mobile versions differed from desktop (text colour/…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3900/5/24
HCP Hospitality & Meetings Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
An ex-employee complained about two AstraZeneca UK oncology-related events.Event 1 (31 Jan 2024, Liverpool conference): Alleged a retired professor speaker was bought “numerous” alcoholic drink…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3903/5/24
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Complainant v GSK (Blenrep website safety claim)
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3736/2/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AAA website
An anonymous, contactable health professional complained about AAA’s “RLT Hub” website accessed via a Medscape email inviting recipients to learn more about Pluvicto.On the HCP page, a bold s…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3782/6/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca Forxiga website renal considerations complaint (AUTH/3782/6/23)
An anonymous health professional complained about AstraZeneca’s promotional website for Forxiga (dapagliflozin), specifically the “Prescribing & Dosing” webpage. The complaint focused on …
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3732/1/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Novartis
An anonymous, non-contactable complainant (described as a health professional) complained about Tasigna (nilotinib) prescribing information linked from Novartis’ UK HCP website (health.novartis.c…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3759/4/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Boehringer Ingelheim clinical trial recruitment flyer at BSG Conference 2023
An anonymous, non-contactable complainant challenged Boehringer Ingelheim’s distribution of an A5 flyer about a Phase 2/3 clinical trial (Brightline-1) at the British Sarcoma Group (BSG) Conferen…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3761/4/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Samsung Bioepis
A concerned health professional complained about a Samsung Bioepis senior UK employee reposting and ‘liking’ a corporate LinkedIn post.The post announced a positive CHMP opinion for a Samsung B…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3758/4/23
Social Media & Digital Upheld 🏥 Oncology ▶ Video 🎙 Podcast
ALK-Abelló
An anonymous, non-contactable complainant alleged an ALK-Abelló representative posted about the prescription only medicine (POM) Jext (adrenaline tartrate) on Facebook and asked friends to share i…
Clauses: 9.1,9.2
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3796/7/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca breached Clause 3.1 after UK employee ‘liked’ third-party LinkedIn post about phase 3 da
A complaint alleged AstraZeneca was promoting an off-licence/unlicensed medicine (datopotamab deruxtecan) to the public on LinkedIn after an AstraZeneca UK employee ‘liked’ a third-party post a…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3784/6/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
A third party posted on LinkedIn naming four AstraZeneca oncology medicines: Tagrisso, Lynparza, Enhertu and Calquence.The post included efficacy messaging (eg Tagrisso trial data “cut the risk o…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3800/7/23
HCP Hospitality & Meetings Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
Employee complaint alleging MEGS used to promote Imfinzi (No breach)
An AstraZeneca employee complained that during Oct 2020 (COVID-19 period) AstraZeneca Oncology used a Medical and Educational Goods and Services (MEGS) programme (“Auxilium CRT”) to promote Imf…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3801/7/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
An anonymous complainant alleged a very senior UK-based AstraZeneca leader’s LinkedIn profile ‘About’ section referenced multiple AstraZeneca medicines by brand name (eg Tagrisso, Imfinzi, Im…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3729/1/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
Complaint 1 (Jan 2022 webinar): A UK virtual “Early Stage Think Tank”/“Surgical Think Tank” meeting was presented as non-promotional, but the Panel considered it promotional given the conte…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3774/6/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
An anonymous, contactable complainant (who later became non-contactable) complained about senior global UK-based AstraZeneca employees’ activity on LinkedIn.Two historical LinkedIn posts were cit…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3813/8/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
AstraZeneca
A third-party institution posted on LinkedIn about a pre-clinical study discussing resistance to osimertinib and how it might be reversed/restored in certain EGFR-mutant lung tumours.Three UK-based…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3810/8/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
GSK
An anonymous, non-contactable complainant (ex-employee) alleged a GSK employee shared a LinkedIn post about Jemperli’s (dostarlimab) US licence expansion, linking to a GSK press release, and that…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3823/9/23
Social Media & Digital Not Upheld 🏥 Oncology ▶ Video 🎙 Podcast
GSK LinkedIn ‘likes’ on US momelotinib approval posts
An anonymous, non-contactable complainant alleged LinkedIn activity by GSK staff amounted to promotion to the public and lacked obligatory information (“No PI or black triangle”). The LinkedIn …
Clauses: NONE
2023 🔒 Subscribe
1 2 3 4 Next → Page 1 of 10 — 218 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews